| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7799960 | European Journal of Medicinal Chemistry | 2015 | 6 Pages |
Abstract
The ELISA assay of a focused kinase library yielded the indolinone as PLK4 inhibitor. Extensive modifications generated CFI-400945, which has entered phase I clinical trials for cancer therapy. However, the kinase selectivity is the major concern that needs to be further investigated.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Bin Yu, Zhiqiang Yu, Ping-Ping Qi, De-Quan Yu, Hong-Min Liu,